- Home
- LAR vs ATAI Comparison
LAR vs ATAI Comparison
Compare LAR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAR
- ATAI
- Stock Information
- Founded
- LAR 2007
- ATAI 2018
- Country
- LAR Switzerland
- ATAI Germany
- Employees
- LAR N/A
- ATAI N/A
- Industry
- LAR
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- LAR
- ATAI Health Care
- Exchange
- LAR NYSE
- ATAI Nasdaq
- Market Cap
- LAR 322.2M
- ATAI 282.6M
- IPO Year
- LAR N/A
- ATAI 2021
- Fundamental
- Price
- LAR $1.73
- ATAI $2.31
- Analyst Decision
- LAR Buy
- ATAI Strong Buy
- Analyst Count
- LAR 1
- ATAI 3
- Target Price
- LAR $3.00
- ATAI $10.50
- AVG Volume (30 Days)
- LAR 958.0K
- ATAI 2.2M
- Earning Date
- LAR 05-14-2025
- ATAI 05-14-2025
- Dividend Yield
- LAR N/A
- ATAI N/A
- EPS Growth
- LAR N/A
- ATAI N/A
- EPS
- LAR N/A
- ATAI N/A
- Revenue
- LAR N/A
- ATAI $1,863,000.00
- Revenue This Year
- LAR N/A
- ATAI $242.21
- Revenue Next Year
- LAR N/A
- ATAI N/A
- P/E Ratio
- LAR N/A
- ATAI N/A
- Revenue Growth
- LAR N/A
- ATAI 572.56
- 52 Week Low
- LAR $1.73
- ATAI $1.03
- 52 Week High
- LAR $4.60
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- LAR N/A
- ATAI 76.68
- Support Level
- LAR N/A
- ATAI $1.38
- Resistance Level
- LAR N/A
- ATAI $2.38
- Average True Range (ATR)
- LAR 0.00
- ATAI 0.18
- MACD
- LAR 0.00
- ATAI 0.07
- Stochastic Oscillator
- LAR 0.00
- ATAI 93.03
About LAR LITHIUM ARGENTINA AG
Lithium Argentina is a pure-play lithium producer. The company owns two neighboring lithium brine resources in northwest Argentina: Cauchari-Olaroz and Pastos Grandes. Cauchari-Olaroz entered production in 2023, while Pastos Grandes is still in development. Lithium Argentina plans for both resources to be fully integrated with onside downstream processing capabilities and will sell into the lithium chemical market.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.